Literature DB >> 8665853

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

R Pinkas-Kramarski1, L Soussan, H Waterman, G Levkowitz, I Alroy, L Klapper, S Lavi, R Seger, B J Ratzkin, M Sela, Y Yarden.   

Abstract

The ErbB family includes two receptors, ErbB-1 and ErbB-3, that respectively bind to epidermal growth factor and Neu differentiation factor, and an orphan receptor, ErbB-2. Unlike ErbB-1 and ErbB-2, the intrinsic tyrosine kinase of ErbB-3 is catalytically impaired. By using interleukin-3-dependent cells that ectopically express the three ErbB proteins or their combinations, we found that ErbB-3 is devoid of any biological activity but both ErbB-1 and ErbB-2 can reconstitute its extremely potent mitogenic activity. Transactivation of ErbB-3 correlates with heterodimer formation and is reflected in receptor phosphorylation and the transregulation of ligand affinity. Inter-receptor interactions enable graded proliferative and survival signals: heterodimers are more potent than homodimers, and ErbB-3-containing complexes, especially the ErbB-2/ErbB-3 heterodimer, are more active than ErbB-1 complexes. Nevertheless, ErbB-1 signaling displays dominance over ErbB-3 when the two receptors are coexpressed. Although all receptor combinations activate the mitogen-activated protein kinases ERK and c-Jun kinase, they differ in their rate of endocytosis and in coupling to intervening signaling proteins. It is conceivable that combinatorial receptor interactions diversify signal transduction and confer double regulation, in cis and in trans, of the superior mitogenic activity of the kinase-defective ErbB-3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665853      PMCID: PMC450177     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  63 in total

Review 1.  Dimerization of cell surface receptors in signal transduction.

Authors:  C H Heldin
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

2.  Intracellular expression of single chain antibodies reverts ErbB-2 transformation.

Authors:  R R Beerli; W Wels; N E Hynes
Journal:  J Biol Chem       Date:  1994-09-30       Impact factor: 5.157

3.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

Authors:  P M Guy; J V Platko; L C Cantley; R A Cerione; K L Carraway
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

Review 4.  A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling.

Authors:  K L Carraway; L C Cantley
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  NDF/heregulin stimulates the phosphorylation of Her3/erbB3.

Authors:  Y A Kita; J Barff; Y Luo; D Wen; D Brankow; S Hu; N Liu; S A Prigent; W J Gullick; M Nicolson
Journal:  FEBS Lett       Date:  1994-07-25       Impact factor: 4.124

6.  ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.

Authors:  E Tzahar; G Levkowitz; D Karunagaran; L Yi; E Peles; S Lavi; D Chang; N Liu; A Yayon; D Wen
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

7.  Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product.

Authors:  H H Kim; S L Sierke; J G Koland
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

Review 8.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor.

Authors:  I Alroy; T L Towers; L P Freedman
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

10.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.

Authors:  R Ben-Levy; H F Paterson; C J Marshall; Y Yarden
Journal:  EMBO J       Date:  1994-07-15       Impact factor: 11.598

View more
  221 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.

Authors:  C A Bell; J A Tynan; K C Hart; A N Meyer; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 3.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 4.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 5.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

6.  Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands.

Authors:  Timothy J Gollan; Michael R Green
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 8.  Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling.

Authors:  Joyce A Schroeder; Leslie F Jackson; David C Lee; Todd D Camenisch
Journal:  J Mol Med (Berl)       Date:  2003-06-25       Impact factor: 4.599

Review 9.  Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

Authors:  Ishwaria M Subbiah; Ana Maria Gonzalez-Angulo
Journal:  Curr Treat Options Oncol       Date:  2014-03

10.  ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Authors:  M A Olayioye; D Graus-Porta; R R Beerli; J Rohrer; B Gay; N E Hynes
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.